The impact of pharmaceutical innovation on longevity, quality of life, and medical expenditure
|
|
- Arlene Sharp
- 5 years ago
- Views:
Transcription
1 The impact of pharmaceutical innovation on longevity, quality of life, and medical expenditure Frank R. Lichtenberg Columbia University and National Bureau of Economic Research 1
2 Hypothesis I have performed numerous studies that have investigated the hypothesis that the health and longevity of a population depends on how technologically advanced the medical goods (including drugs) and services its members use are. Furthermore, how technologically advanced a medical good or service is depends on its vintage, defined as its year of invention or first use. Wine: older (earlier vintage) products are of higher quality Drugs: newer (later vintage) products are of higher quality Nobel laureate Robert Solow introduced the concept of vintage into economic analysis. Solow s basic idea was that technical progress (which results from R&D investment) is built into machines and other goods and that this must be taken into account when making empirical measurements of their roles in production. 2
3 Company-funded R&D expenditure as % of sales, U.S., % 2% 4% 6% 8% 10% 12% 14% Pharmaceuticals and medicines 12.7% Computer and electronic products 8.4% Aerospace products and parts 5.1% Manufacturing industries 3.7% All industries 3.5% Source: U.S. National Science Foundation, Science and Engineering Indicators 2010, appendix table
4 2011 U.S. Biomedical and Health R&D Spending (millions of dollars) $19,113, 14% $39,552, 29% $77,580, 57% Industry Federal government Other 4
5 R&D, technological progress, and economic growth R&D Private Public Technological progress Embodied (in new goods) Disembodied Economic growth GDP growth Longevity growth 5
6 Has medical innovation reduced cancer mortality? CESifo Economic Studies, published online 14 November 2013.
7 Age-adjusted U.S. cancer incidence and mortality rates, i n c i d e n c e r a t e Incidence: 9 SEER registries Mortality: All Malignant Cancers m o r t a l i t y r a t e During the period I studied ( ), the age-adjusted cancer mortality rate declined 19%; the ageadjusted cancer incidence rate declined by only 4%. 7
8 Age-adjusted mortality rate, six major cancer sites, (index: 1996 = 1.00) Lung and Bronchus Colon excluding Rectum Breast Prostate Pancreas Non-Hodgkin Lymphoma
9 Log change in age-adjusted mortality rate, , top 10 cancer sites (ranked by average mortality rate) Prostate Non-Hodgkin Lymphoma Stomach Breast Colon excluding Rectum Lung and Bronchus Ovary Brain and Other Nervous System Pancreas Urinary Bladder Log change in mortality rate, adjusted for log change in incidence Log change in mortality rate
10 Key hypothesis: Mortality rates declined more for cancer sites that were subject to more treatment innovation, controlling for change in incidence, etc.
11 Hypothesis: the conditional mortality rate (P(death from cancer cancer diagnosis)) is inversely related to the average (current and lagged) quality of medical procedures quality of medical procedures conditional mortality rate Quality of medical procedures is not directly observable, but 11
12 Hypothesis: treatment quality is directly related to treatment vintage vintage of medical procedures quality of medical procedures conditional mortality rate Drug vintage is defined as the original FDA approval year of the drug s active ingredient(s) 12
13 Ten drugs with the largest increase in share of all cancer drug procedures 0% 1% 2% 3% 4% 5% 6% PALONOSETRON HYDROCHLORIDE (2003) 0.0% 5.6% D r u g DIPHENHYDRAMINE HYDROCHLORIDE (1946) TRASTUZUMAB (1998) 0.0% 2.1% 2.7% 5.4% ( F D A ZOLEDRONIC ACID (2001) 0.0% 1.8% a p p r o v a l BEVACIZUMAB (2004) PEGFILGRASTIM (2002) DOCETAXEL (1996) 0.0% 0.0% 0.0% 1.8% 1.7% 1.5% share of drug procedures in 1996 share of drug procedures in 2009 y e a r ) GEMCITABINE HYDROCHLORIDE (1996) GRANISETRON HYDROCHLORIDE (1993) 0.0% 0.0% 1.5% 1.4% FENTANYL CITRATE (1968) 0.1% 1.5% 13
14 Fraction of drug procedures that were post-1995 drug procedures, 6 major cancer sites, % 35% 30% Lung and Bronchus Colon excluding Rectum Breast Prostate Pancreas Non-Hodgkin Lymphoma 25% 20% 15% 10% 5% 0%
15 Fraction of imaging procedures that were advanced imaging procedures, 6 major cancer sites, % 80% 70% 60% 50% 40% 30% Lung and Bronchus 20% Colon excluding Rectum Breast Prostate 10% Pancreas Non-Hodgkin Lymphoma 0%
16 3 major reasons for the 13.8% decline in the cancer mortality rate during Drug innovation reduced the cancer mortality rate by 8.0%. Imaging innovation reduced the cancer mortality rate by 4.0%. The 3% decline in the cancer incidence rate is estimated to have reduced the cancer mortality rate by just 1.2%. Estimates of the effects of radiation and surgical innovation were not significant, but these types of innovation are more difficult to measure than drug and imaging innovation. 16
17 Benefits vs. costs of innovation Murphy and Topel (2006) estimated that a 1 percent reduction in [U.S.] cancer mortality would be worth nearly $500 billion. This implies that the value of the mortality reduction resulting from cancer drug innovation was $4.0 trillion (= 8.0 * $500 billion). Data from IMS Health indicate that total U.S. expenditure on new (post-1995) cancer drugs in 2009 was $31.0 billion If Murphy and Topel s and my calculations are correct, the cost of new cancer drugs is less than 1% of the value of the mortality reduction they yielded. 17
18 The impact of pharmaceutical innovation on disability days and the use of medical services in the United States,
19 8.5 Mean number of work-loss days per year, employed persons 18 years of age and older NHIS: Work loss days MEPS: Work loss days MEPS: Work loss days + additional bed days 5.5 y = 6E+36e x 4.5 y = 1E+16e x 3.5 y = 3E+39e x Source: author's calculations based on (1) NHIS data from Minnesota Population Center and State Health Access Data Assistance Center, Integrated Health Interview Series: Version 4.0. Minneapolis: University of Minnesota, 2011, and (2) MEPS Supplemental Public Use Files ( ) and full-year consolidated data files ( ) 19
20 Mean number of school days missed per year because of illness or injury for children aged NHIS: School loss days MEPS: School loss days MEPS: School loss days + additional bed days y = 3E+08e x 3 y = 6E+41e x 2.5 y = 2E+40e x Source: author's calculations based on (1) NHIS data from Minnesota Population Center and State Health Access Data Assistance Center, Integrated Health Interview Series: Version 4.0. Minneapolis: University of Minnesota, 2011, and (2) MEPS Supplemental Public Use Files ( ) and full-year consolidated data files ( ) 20
21 Hypothesis: medical innovation especially pharmaceutical innovation has played an important role in reducing disability days
22 Hypothesis: disability is inversely related to Rx quality Rx quality Disability Rx quality is not directly observable, but 22
23 Hypothesis: Rx quality is directly related to Rx vintage Rx vintage Rx quality Disability Rx vintage is defined as the original FDA approval year of the drug s active ingredient(s) 23
24 Other medical innovation The number of people exposed to pharmaceutical innovation tends to be much larger than the number of people exposed to other types of medical innovation: for example, in 2007, 62% of Americans consumed prescription drugs, while only 8% of Americans were admitted to hospitals. Pharmaceuticals are more research-intensive than other types of medical care: in 2007, prescription drugs accounted for 10% of U.S. health expenditure, but more than half of U.S. funding for biomedical research came from pharmaceutical and biotechnology firms. Much of the rest came from the federal government (i.e. the NIH), and new drugs often build on upstream government research (Sampat and Lichtenberg, 2011). Evidence presented in Lichtenberg (2013) suggests that the rate of pharmaceutical innovation is uncorrelated across diseases with rates of innovation in imaging and other procedures. 24
25 Econometric model to assess the impact of pharmaceutical innovation on disability days and the use of medical services ln(y ct ) = p RX_VINTAGE ct + g Z ct + a c + d t + e ct (1) Y ct = a measure of disability days or the use of medical services associated with medical condition c in period t RX_VINTAGE ct = a measure of the mean vintage of prescription drugs used to treat medical condition c in period t Z ct = a measure of other attributes of medical condition c in period t a c = a fixed effect for medical condition c d t = a fixed effect for period t 25
26 Estimates of disability-days and medical service use models Medical conditions that had larger increases in the number of post-1990 drugs per person tended to have larger declines in (per capita and total) disability days and use of almost all non-drug medical services. An increase in drug quality improves health more when the average quantity of drugs consumed is high. 26
27 Cost and benefits per medical condition in 2010 of new (post-1990) drugs Cost of new (post-1990) drugs $42 Benefits of new drugs value of the reduction in the number of work loss days $14 value of the reduction in the number of other bed days $10 reduction in hospital expenditure $39 reduction in office-based expenditure $10 reduction in emergency room expenditure $6 reduction in home health expenditure $5 reduction in old (pre-1991) drug expenditure $11 Total value of benefits $95 27
28 Conclusions The cost of new cancer drugs is less than 1% of the value of the mortality reduction they yielded Pharmaceutical innovation has reduced work-loss and school-loss days Pharmaceutical innovation has reduced non-drug medical expenditure (e.g. hospital expenditure) more than it has increased drug expenditure Good access to new drugs is needed to ensure that society enjoys the benefits of pharmaceutical innovation 28
Research proposal. The impact of medical knowledge accumulation and diffusion on health: evidence from Medline and other N.I.H.
1 Research proposal The impact of medical knowledge accumulation and diffusion on health: evidence from Medline and other N.I.H. data Frank R. Lichtenberg Columbia University and National Bureau of Economic
More informationHas medical innovation reduced cancer mortality?
Has medical innovation reduced cancer mortality? Frank R. Lichtenberg Columbia University and National Bureau of Economic Research frank.lichtenberg@columbia.edu This research was supported by Siemens
More informationThe impact of pharmaceutical innovation on New Zealand cancer patients
The impact of pharmaceutical innovation on New Zealand cancer patients Frank R. Lichtenberg, Ph.D Columbia University and National Bureau of Economic Research New medicines have helped people with cancer
More informationHow Cost-Effective Are New Cancer Drugs in the U.S.?
How Cost-Effective Are New Cancer Drugs in the U.S.? Frank R. Lichtenberg How cost-effective are new cancer drugs in the U.S.? Frank R. Lichtenberg frl1@columbia.edu Columbia University, National Bureau
More informationThe contribution of. improved outcomes and economic growth. Frank Lichtenberg. Content
The contribution of pharmaceutical innovation to longevity, improved outcomes and economic growth Frank Lichtenberg Lisbon 1 May 211 Content Contribution of new medicines to longevity increase Evidence
More informationForum for Health Economics & Policy
Forum for Health Economics & Policy Volume 13, Issue 2 2010 Article 11 (HEALTH ECONOMICS) Are Increasing 5-Year Survival Rates Evidence of Success Against Cancer? A Reexamination Using Data from the U.S.
More informationEstimated Minnesota Cancer Prevalence, January 1, MCSS Epidemiology Report 04:2. April 2004
MCSS Epidemiology Report 04:2 Suggested citation Perkins C, Bushhouse S.. Minnesota Cancer Surveillance System. Minneapolis, MN, http://www.health.state.mn.us/divs/hpcd/ cdee/mcss),. 1 Background Cancer
More informationEpidemiology in Texas 2006 Annual Report. Cancer
Epidemiology in Texas 2006 Annual Report Cancer Epidemiology in Texas 2006 Annual Report Page 94 Cancer Incidence and Mortality in Texas, 2000-2004 The Texas Department of State Health Services Texas Cancer
More informationF. Lichtenberg, The contribution of pharmaceutical innovation to longevity growth in Germany and France, Pharmacoeconomics (In press)
The contribution of pharmaceutical innovation to longevity, improved outcomes and economic growth Frank Lichtenberg Lisbon 10 May 2011 Content Contribution of new medicines to longevity increase Evidence
More informationThe impact of pharmaceutical innovation on mortality, disability, and hospitalization:
The impact of pharmaceutical innovation on mortality, disability, and hospitalization: evidence from 4 studies Frank R. Lichtenberg, PhD frl1@columbia.edu Columbia University and National Bureau of Economic
More informationNational Cancer Statistics in Korea, 2014
National Cancer Statistics in Korea, 2014 2016. 12. 20. Korea Central Cancer Registry Cancer Incidence in Korea, 2014 National Cancer Incidence, 2014 Trends in Cancer Incidence by Sex and Year * Dark colored
More informationHas medical innovation reduced cancer mortality? Frank R. Lichtenberg.
Has medical innovation reduced cancer mortality? Frank R. Lichtenberg frank.lichtenberg@columbia.edu Columbia University and National Bureau of Economic Research 30 November 2010 This research was supported
More informationCANCER FACTS & FIGURES For African Americans
CANCER FACTS & FIGURES For African Americans Pennsylvania, 2006 Pennsylvania Cancer Registry Bureau of Health Statistics and Research Contents Data Hightlights...1 Pennsylvania and U.S. Comparison...5
More informationNBER WORKING PAPER SERIES THE EFFECT OF CHANGES IN DRUG UTILIZATION ON LABOR SUPPLY AND PER CAPITA OUTPUT. Frank R. Lichtenberg
NBER WORKING PAPER SERIES THE EFFECT OF CHANGES IN DRUG UTILIZATION ON LABOR SUPPLY AND PER CAPITA OUTPUT Frank R. Lichtenberg Working Paper 9139 http://www.nber.org/papers/w9139 NATIONAL BUREAU OF ECONOMIC
More informationThe effect of new cancer drug approvals on the life expectancy of American cancer patients,
Economics of Innovation and New Technology Vol. 18, No. 5, July 2009, 407 428 The effect of new cancer drug approvals on the life expectancy of American cancer patients, 1978 2004 Frank R. Lichtenberg*
More informationColorectal Cancer Screening
Colorectal Cancer Screening December 5, 2017 Connecticut Cancer Partnership 14th Annual Meeting Xavier Llor, M.D., PhD. Associate Professor of Medicine Co-Director, Cancer Genetics and Prevention Program
More informationEmployer-provided health insurance is
JOEM Volume 47, Number 4, April 2005 373 Availability of New Drugs and Americans Ability to Work Frank R. Lichtenberg, PhD Objective: The objective of this work was the investigation of the extent to which
More informationCancer in New Mexico 2017
Cancer in New Mexico 0 Please contact us! Phone: 0-- E-Mail: nmtr-info@salud.unm.edu URL: nmtrweb.unm.edu TABLE OF CONTENTS Introduction... New Cases of Cancer Estimated Number of New Cancer Cases Description
More informationAn Unhealthy America: The Economic Burden of Chronic Disease Charting a New Course to Save Lives and Increase Productivity and Economic Growth
An Unhealthy America: The Economic Burden of Chronic Disease Charting a New Course to Save Lives and Increase Productivity and Economic Growth Ross DeVol Director, Center for Health Economics Director,
More informationCancer in New Mexico 2014
Cancer in New Mexico 2014 Please contact us! Phone: 505-272-5541 E-Mail: info@nmtr.unm.edu http://som.unm.edu/nmtr/ TABLE OF CONTENTS Introduction... 1 New Cases of Cancer: Estimated Number of New Cancer
More informationStatistical models can give useful insights into why mortality is falling
Far fewer Australians are dying early in life Premature mortality is defined as people dying before age 75. Reducing premature death is a crucial public health issue. In Australia between 1998 and 2011
More informationInformation Services Division NHS National Services Scotland
Cancer in Scotland October 2012 First published in June 2004, revised with each National Statistics publication Next due for revision April 2013 Information Services Division NHS National Services Scotland
More informationCommon Questions about Cancer
6 What is cancer? Cancer is a group of diseases characterized by uncontrolled growth and spread of abnormal cells. The cancer cells form tumors that destroy normal tissue. If cancer cells break away from
More informationDo Firms Underinvest In Long-Term Research? Evidence From Cancer Clinical Trials
SIEPR policy brief Stanford University May 2014 Stanford Institute for Economic Policy Research on the web: http://siepr.stanford.edu Do Firms Underinvest In Long-Term Research? Evidence From Cancer Clinical
More informationNation nal Cancer Institute. Prevalence Projections: The US Experience
Nation nal Cancer Institute Prevalence Projections: The US Experience State of Art Methods for the Analysis of Population- Based Cancer Data January 22-23, 2014 Ispra, Italy U.S. DEPARTMENT OF HEALTH AND
More informationAn Unhealthy America: The Economic Burden of Chronic Disease Charting a New Course to Save Lives and Increase Productivity and Economic Growth
An Unhealthy America: The Economic Burden of Chronic Disease Charting a New Course to Save Lives and Increase Productivity and Economic Growth Kevin Klowden Managing Economist Milken Institute (310) 570
More informationAPPENDIX ONE: ICD CODES
APPENDIX ONE: ICD CODES ICD-10-AM ICD-9-CM Malignant neoplasms C00 C97 140 208, 238.6, 273.3 Lip, oral cavity and pharynx C00 C14 140 149 Digestive organs C15 C26 150 157, 159 Oesophagus 4 C15 150 excluding
More informationThe Benefits and Costs of Newer Drugs: Evidence from the 1996 Medical Expenditure Panel Survey
The Benefits and Costs of Newer Drugs: Evidence from the 1996 Medical Expenditure Panel Survey by Frank R. Lichtenberg frank.lichtenberg@columbia.edu Columbia University and National Bureau of Economic
More informationNATIONAL CANCER CONTROL PROGRAMME NATIONAL STRATEGY FOR THE SAFE ADMINISTATION OF CANCER DRUGS
NATIONAL CANCER CONTROL PROGRAMME NATIONAL STRATEGY FOR THE SAFE ADMINISTATION OF CANCER DRUGS Dr Susan O Reilly MB, FRCPC, FRCPI National Director National Cancer Control Programme IMSN Networking for
More informationExpenditure Share United States, 2003
Expenditure Share United States, 2003 Source: MEPS Chronic Disease Share of MEPS Expenditure ( Percent ) Share of Health Care Expenditure Breast Cancer 0.5 0.3 Colon Cancer 0.8 0.5 Lung Cancer 0.6 0.3
More informationCancer in Rural Illinois, Incidence, Mortality, Staging, and Access to Care. April 2014
Cancer in Rural Illinois, 1990-2010 Incidence, Mortality, Staging, and Access to Care April 2014 Prepared by Whitney E. Zahnd, MS Research Development Coordinator Center for Clinical Research Southern
More informationEffective Technology and Its Economic Benefits: The Case of Colonoscopy
Effective Technology and Its Economic Benefits: The Case of Colonoscopy Ross C. DeVol, Chief Research Officer Milken Institute The 2015 Dialogue for Action: Expanding Access Through Innovation Renaissance
More informationCancer in Northeastern Pennsylvania: Incidence and Mortality of Common Cancers
Cancer in Northeastern Pennsylvania: Incidence and Mortality of Common Cancers Samuel M. Lesko, MD, MPH Medical Director Karen Ryczak, RN Surveillance Coordinator December 2014 334 Jefferson Avenue, Scranton,
More informationCancer Facts & Figures for African Americans
Cancer Facts & Figures for African Americans What is the Impact of Cancer on African Americans in Indiana? Table 12. Burden of Cancer among African Americans Indiana, 2004 2008 Average number of cases
More informationCancer in Northeastern Pennsylvania: Incidence and Mortality of Common Cancers
Cancer in Northeastern Pennsylvania: Incidence and Mortality of Common Cancers Samuel M. Lesko, MD, MPH Medical Director Karen Ryczak, RN Surveillance Coordinator November 2018 334 Jefferson Avenue, Scranton,
More informationCancer in Utah: An Overview of Cancer Incidence and Mortality from
Cancer in Utah: An Overview of Cancer Incidence and Mortality from 1973-2010 A publication of the Utah Cancer Registry January 2014 Prepared by: C. Janna Harrell, MS Senior Research Analyst Kimberly A.
More informationCancer in Northeastern Pennsylvania: Incidence and Mortality of Common Cancers
Cancer in Northeastern Pennsylvania: Incidence and Mortality of Common Cancers Samuel M. Lesko, MD, MPH Medical Director Karen Ryczak, RN Surveillance Coordinator December 2017 334 Jefferson Avenue, Scranton,
More informationThe Cancer Burden in California. Janet Bates MD MPH California Cancer Registry California Department of Public Health April 25, 2012
The Cancer Burden in California Janet Bates MD MPH California Cancer Registry California Department of Public Health April 25, 2012 Goals Introduce you to the California Cancer Registry (CCR) Provide an
More informationProductivity Change in Health Care
Productivity Change in Health Care The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters Citation Cutler, David and Mark McClellan.
More informationAn Unhealthy America: The Economic Burden of Chronic Disease
An Unhealthy America: The Economic Burden of Chronic Disease Charting a New Course to Save Lives and Increase Productivity and Economic Growth February 2008 Today s Presentation General trends in chronic
More informationCancer survival in Seoul, Republic of Korea,
Cancer survival in Seoul, Republic of Korea, 1993 1997 Ahn YO and Shin MH Abstract The Seoul cancer registry was established in 1991. Cancer is a notifiable disease, and registration of cases is done by
More informationCancer prevalence. Chapter 7
Chapter 7 Cancer prevalence Prevalence measures the number of people diagnosed with cancer who are still alive. This chapter presents current and historical statistics on cancer prevalence in Ontario.
More informationOverview of 2009 Hong Kong Cancer Statistics
Overview of 2009 Hong Kong Cancer Statistics Cancer Registration in Hong Kong The Hong Kong Cancer Registry has since 1963 been providing population-based cancer data for epidemiological research and healthcare
More informationTrends in Pneumonia and Influenza Morbidity and Mortality
Trends in Pneumonia and Influenza Morbidity and Mortality American Lung Association Epidemiology and Statistics Unit Research and Health Education Division November 2015 Page intentionally left blank Introduction
More informationNIH Public Access Author Manuscript Cancer. Author manuscript; available in PMC 2006 December 17.
NIH Public Access Author Manuscript Published in final edited form as: Cancer. 2005 December 15; 104(12 Suppl): 2989 2998. 1999 2001 Cancer Mortality Rates for Asian and Pacific Islander Ethnic Groups
More informationTrends in Cancer Survival in NSW 1980 to 1996
Trends in Cancer Survival in NSW 19 to 1996 Xue Q Yu Dianne O Connell Bruce Armstrong Robert Gibberd Cancer Epidemiology Research Unit Cancer Research and Registers Division The Cancer Council NSW August
More informationPharmaceutical market
Pharmaceutical market I s P h a r m a a s i m p o r t a n t a s i t s e m p l o y e e s t h i n k? Our lives are getting longer In Europe, over the last 65 years, we have obeserved a significant increase
More informationAttracting Talent & Driving Growth in Wisconsin
Attracting Talent & Driving Growth in Wisconsin v 2 nd Annual Future Wisconsin Economic Summit Kevin Conroy, Chairman & CEO December 9, 2015 WMC Foundation: Second Annual Future Wisconsin Economic Summit
More informationInformation Services Division NHS National Services Scotland
Cancer in Scotland April 2013 First published in June 2004, revised with each National Statistics publication Next due for revision October 2013 Information Services Division NHS National Services Scotland
More informationAppendix C CHANGING THE TRAJECTORY:
Appendix C CHANGING THE TRAJECTORY: Impact of a Hypothetical Treatment That Slows the Progression of Alzheimer s In addition to the delayed onset scenario discussed in the report, another potential scenario
More informationCancer survival in Bhopal, India,
Chapter 13 Cancer survival in Bhopal, India, 1991 1995 Dikshit R, Kanhere S and Surange S Abstract The Bhopal population-based cancer registry was established in 1986 under the national cancer registry
More informationWashington, DC Washington, DC Washington, DC Washington, DC 20510
March 12, 2018 The Honorable Thad Cochran The Honorable Patrick Leahy Chairman Vice Chairman Committee on Appropriations Committee on Appropriations Washington, DC 20510 Washington, DC 20510 The Honorable
More informationSamuel M. Lesko, MD, MPH Director of Research/Medical Director
Cancer in Northeastern Pennsylvania: Incidence, Mortality and Survival for Common Cancers Samuel M. Lesko, MD, MPH Director of Research/Medical Director May 11 334 Jefferson Avenue, Scranton, PA 1851-57-941-7984
More informationANNUAL CANCER REGISTRY REPORT-2005
ANNUAL CANCER REGISTRY REPORT-25 CANCER STATISTICS Distribution of neoplasms Of a total of 3,115 new neoplasms diagnosed or treated at the Hospital from January 25 to December, 25, 1,473 were seen in males
More informationAn Unhealthy America: The Economic Burden of Chronic Disease Charting a New Course to Save Lives and Increase Productivity and Economic Growth
An Unhealthy America: The Economic Burden of Chronic Disease Charting a New Course to Save Lives and Increase Productivity and Economic Growth Ross DeVol Director, Center for Health Economics Director,
More informationTruman Medical Center-Hospital Hill Cancer Registry 2014 Statistical Summary Incidence
Truman Medical Center-Hospital Hill Cancer Registry 2014 Statistical Summary Incidence In 2014, there were 452 new cancer cases diagnosed and or treated at Truman Medical Center- Hospital Hill and an additional
More informationBurden of Cancer in California
Burden of Cancer in California California Cancer Reporting and Epidemiologic Surveillance Institute for Population Health Improvement UC Davis Health August 22, 2018 Outline 1. Incidence and Mortality
More informationCancer Dispari,es in Indiana
Cancer Dispari,es in Indiana Susan M. Rawl, PhD, RN, FAAHB, FAAN Professor, Indiana University School of Nursing Co- Leader, Cancer PrevenEon & Control Program Indiana University Simon Cancer Center Indiana
More informationThe Contribution of Health Industry to the Expansion of the Country s Development Perspective
17 th Annual Conference HealthWorld 2018 The Contribution of Health Industry to the Expansion of the Country s Development Perspective 11.06.18 Makis Papataxiarchis President, Pharma Innovation Forum,
More informationOverview of 2010 Hong Kong Cancer Statistics
Overview of 2010 Hong Kong Cancer Statistics Cancer Registration in Hong Kong The Hong Kong Cancer Registry has since the 1960s been providing population-based cancer data for epidemiological research
More informationOutcomes Report: Accountability Measures and Quality Improvements
Outcomes Report: Accountability Measures and Quality Improvements The FH Memorial Medical Center s Cancer Committee ensures that patients with cancer are treated according to the nationally accepted measures.
More informationTHE BURDEN OF CANCER IN NEBRASKA: RECENT INCIDENCE AND MORTALITY DATA
THE BURDEN OF CANCER IN NEBRASKA: RECENT INCIDENCE AND MORTALITY DATA Presented by: Bryan Rettig, MS Nebraska Dept. of Health & Human Services Division of Public Health May 31, 2017 Nebraska Cancer Registry
More informationEvaluation of Ancestry Information Markers (AIMs) from Previous ACOSOG/CALGB/NCCTG Trials
Evaluation of Ancestry Information Markers (AIMs) from Previous ACOSOG/CALGB/NCCTG Trials Mary Beth Terry, PhD Department of Epidemiology Mailman School of Public Health Racial and Ethnic Disparities in
More informationWhat is the Impact of Cancer on African Americans in Indiana? Average number of cases per year. Rate per 100,000. Rate per 100,000 people*
What is the Impact of Cancer on African Americans in Indiana? Table 13. Burden of Cancer among African Americans Indiana, 2008 2012 Average number of cases per year Rate per 100,000 people* Number of cases
More informationCancer survival in Shanghai, China,
Cancer survival in Shanghai, China, 1992 1995 Xiang YB, Jin F and Gao YT Abstract The Shanghai cancer registry, established in 1963, is the oldest one in mainland China; cancer registration is entirely
More informationThe National Academies
The National Academies Building the 21 st Century: U.S. China Cooperation on Science Technology and Innovation Anna D. Barker, PhD Deputy Director, NCI May 18, 2010 By 2020, Cancer Could Kill 10.3 Million
More informationCancer A Superficial Introduction
Cancer A Superficial Introduction Gabor Fichtinger, Queen s University Cancer some definitions Medical term: malignant neoplasm Class of diseases in which a group of cells display: uncontrolled growth
More informationMedical Progress Report
Medical Progress Report No. 7 October 2008 Alive and Working: How Access to New Drugs has Slowed the Growth in America s Disability Rates Frank R. Lichtenberg Columbia University and National Bureau of
More informationUsing Policy, Programs, and Partnerships to Stamp Out Breast and Cervical Cancers
Using Policy, Programs, and Partnerships to Stamp Out Breast and Cervical Cancers National Conference of State Legislatures Annual Meeting J August 2006 Christy Schmidt Senior Director of Policy National
More information*
Introduction Cancer is complex, can have many possible causes, and is increasingly common. For the U.S. population, 1 in 2 males and 1 in 3 females is at risk of developing cancer in their lifetime. The
More informationComprehensive cancer cover
Retirement Investments Insurance Health Comprehensive cancer cover Life Insurance+ with critical illness and Critical Illness+ Cancer is one of the biggest fears for the British public This is why our
More informationPharmaceutical innovation and cancer survival: U.S. and international evidence. Frank R. Lichtenberg* Columbia University. and
Pharmaceutical innovation and cancer survival: U.S. and international evidence Frank R. Lichtenberg* Columbia University and National Bureau of Economic Research * Graduate School of Business, Columbia
More informationRepublican Research and Practical Center for Radiation Medicine and Human Ecology. Ilya Veyalkin Head of Laboratory of Epidemiology Gomel, Belarus
Republican Research and Practical Center for Radiation Medicine and Human Ecology Ilya Veyalkin Head of Laboratory of Epidemiology Gomel, Belarus The contaminated area in the Republic of Belarus consisted
More informationCancer in Central and South America BOLIVIA
Cancer in Central and South America BOLIVIA This country profile for the Cancer in Central and South America project provides, for each participating cancer registry tables and graphics showing numbers
More informationCancer survival in Hong Kong SAR, China,
Chapter 5 Cancer survival in Hong Kong SAR, China, 1996 2001 Law SC and Mang OW Abstract The Hong Kong cancer registry was established in 1963, and cancer registration is done by passive and active methods.
More informationOncology Therapeutics Market in India to 2018
Oncology Therapeutics Market in India to 2018 Introduction of Market-Based Pricing to Fuel Price Wars and Intense Competition Among Domestic and Multinational Players GBI Research Report Guidance GBI Research
More informationSKCC Protocol Review Committee New Study Application
Instructions: Submit the following documents to prc@jefferson.edu - Completed New Study Application (aka MCSF) - Protocol - Protocol Facilitation Committee Approval (if applicable) - MDG Priority Score
More informationComprehensive cancer cover
Retirement Investments Insurance Health Comprehensive cancer cover Life Insurance+ with critical illness and Critical Illness+ Cancer is one of the biggest fears for the British public This is why our
More informationCANCER RATES AND TRENDS IN NORTHEASTERN MINNESOTA. MCSS Epidemiology Report 97:1. September 1997
CANCER RATES AND TRENDS IN NORTHEASTERN MINNESOTA MCSS Epidemiology Report 97: September 997 Minnesota Cancer Surveillance System Chronic Disease And Environmental Epidemiology Section Minnesota Department
More informationA New Measure to Assess the Completeness of Case Ascertainment
A New Measure to Assess the Completeness of Case Ascertainment Barnali Das, Ph.D. Linda Pickle, Ph.D. Eric J. (Rocky) Feuer, Ph.D. Lin Clegg, Ph.D. Surveillance Research Program, National Cancer Institute
More informationCancer Prevention: the gap between what we know and what we do
Cancer Prevention: the gap between what we know and what we do John D Potter MBBS PhD Public Health Sciences Division Fred Hutchinson Cancer Research Center Global Trends Global Trends Increasing population
More informationSuicides increased in 2014
Causes of death 2014 23 May, 2016 Suicides increased in 2014 Diseases of the circulatory system accounted for 30.7% of the deaths recorded in 2014, 2.4% more than in the previous year. The average age
More informationInformation Services Division NHS National Services Scotland
Cancer in Scotland April 2017 First published in June 2004, revised with each National Statistics publication Next due for revision October 2017 Information Services Division NHS National Services Scotland
More informationIMPACT OF DEVELOPMENT ASSISTANCE FOR HEALTH ON COUNTRY SPENDING
CHAPTER 4: IMPACT OF DEVELOPMENT ASSISTANCE FOR HEALTH ON COUNTRY SPENDING As external health aid has grown in importance in recent years, global health experts have discussed the role that development
More information2011 to 2015 New Cancer Incidence Truman Medical Center - Hospital Hill
Number of New Cancers Truman Medical Center Hospital Hill Cancer Registry 2015 Statistical Summary Incidence In 2015, Truman Medical Center diagnosed and/or treated 406 new cancer cases. Four patients
More informationOverview of 2013 Hong Kong Cancer Statistics
Overview of 2013 Hong Kong Cancer Statistics Cancer Registration in Hong Kong The Hong Kong Cancer Registry (HKCaR) is a population-based cancer registry, collecting the basic demographic data, information
More informationNEZ PERCE COUNTY CANCER PROFILE
NEZ PERCE COUNTY CANCER PROFILE A fact sheet from the Cancer Data Registry of Idaho, Idaho Hospital Association. Cancer Incidence 2010-2014 Cancer Mortality 2011-2015 BRFSS 2011-2015 CANCER Cancer is a
More informationKOOTENAI COUNTY CANCER PROFILE
KOOTENAI COUNTY CANCER PROFILE A fact sheet from the Cancer Data Registry of Idaho, Idaho Hospital Association. Cancer Incidence 2010-2014 Cancer Mortality 2011-2015 BRFSS 2011-2015 CANCER Cancer is a
More informationBOUNDARY COUNTY CANCER PROFILE
BOUNDARY COUNTY CANCER PROFILE A fact sheet from the Cancer Data Registry of Idaho, Idaho Hospital Association. Cancer Incidence 2010-2014 Cancer Mortality 2011-2015 BRFSS 2011-2015 CANCER Cancer is a
More informationClinical Precision for Best Cancer Care. Dee Mathieson Senior Vice President Oncology Business Line Management
Clinical Precision for Best Cancer Care Dee Mathieson Senior Vice President Oncology Business Line Management Optimizing clinical results Key drivers in modern Radiation Therapy Clinical precision Continuous
More informationNBER WORKING PAPER SERIES THE EFFECT OF NEW DRUGS ON MORTALITY FROM RARE DISEASES AND HIV. Frank R. Lichtenberg
NBER WORKING PAPER SERIES THE EFFECT OF NEW DRUGS ON MORTALITY FROM RARE DISEASES AND HIV Frank R. Lichtenberg Working Paper 8677 http://www.nber.org/papers/w8677 NATIONAL BUREAU OF ECONOMIC RESEARCH 1050
More informationADAMS COUNTY CANCER PROFILE
ADAMS COUNTY CANCER PROFILE A fact sheet from the Cancer Data Registry of Idaho, Idaho Hospital Association. Cancer Incidence 2010-2014 Cancer Mortality 2011-2015 BRFSS 2011-2015 CANCER Cancer is a group
More informationBONNER COUNTY CANCER PROFILE
BONNER COUNTY CANCER PROFILE A fact sheet from the Cancer Data Registry of Idaho, Idaho Hospital Association. Cancer Incidence 2010-2014 Cancer Mortality 2011-2015 BRFSS 2011-2015 CANCER Cancer is a group
More informationBINGHAM COUNTY CANCER PROFILE
BINGHAM COUNTY CANCER PROFILE A fact sheet from the Cancer Data Registry of Idaho, Idaho Hospital Association. Cancer Incidence 2011-2015 Cancer Mortality 2012-2016 BRFSS 2011-2016 CANCER Cancer is a group
More informationCancer Statistics, 2008
CA Cancer J Clin 8;58:71 96 Cancer Statistics, 8 Ahmedin Jemal, DVM, PhD; Rebecca Siegel, MPH; Elizabeth Ward, PhD; Yongping Hao, PhD; Jiaquan Xu*, MD; Taylor Murray; Michael J. Thun, MD, MS ABSTRACT Each
More informationCancer in Halton. Halton Region Cancer Incidence and Mortality Report
Cancer in Halton Halton Region Cancer Incidence and Mortality Report 2008 2012 The Regional Municipality of Halton March 2017 Reference: Halton Region Health Department, Cancer in Halton: Halton Region
More informationNEZ PERCE COUNTY CANCER PROFILE
NEZ PERCE COUNTY CANCER PROFILE A fact sheet from the Cancer Data Registry of Idaho, Idaho Hospital Association. Cancer Incidence 2011-2015 Cancer Mortality 2012-2016 BRFSS 2011-2016 CANCER Cancer is a
More informationKOOTENAI COUNTY CANCER PROFILE
KOOTENAI COUNTY CANCER PROFILE A fact sheet from the Cancer Data Registry of Idaho, Idaho Hospital Association. Cancer Incidence 2011-2015 Cancer Mortality 2012-2016 BRFSS 2011-2016 CANCER Cancer is a
More informationTWIN FALLS COUNTY CANCER PROFILE
TWIN FALLS COUNTY CANCER PROFILE A fact sheet from the Cancer Data Registry of Idaho, Idaho Hospital Association. Cancer Incidence 2011-2015 Cancer Mortality 2012-2016 BRFSS 2011-2016 CANCER Cancer is
More informationAmerican Cancer Society Estimated Cancer Deaths by Sex and Age (years), 2013
American Cancer Society Estimated Cancer Deaths by Sex and Age (years), 2013 All ages Younger than 45 45 and Older Younger than 65 65 and Older All sites, men 306,920 9,370 297,550 95,980 210,940 All sites,
More information